ARTICLE INFO

Article Type

Original Research

Authors

Nikounezhad   M. (1 )
Ghazanfari   T. (* )
Askari   N. (2 )
Zarnani   A.H. (3 )
Gohari Moghaddam   K. (4 )
Mirafsharieh   A. (5 )






(* ) Immunoregulation Research Center, Shahed University, Tehran, Iran
(1 ) Immunology Department, Medicine Faculty, Shahed University, Tehran, Iran
(2 ) Biology Department, Basic Sciences Faculty, Shahid Bahonar University, Kerman, Iran
(3 ) Ibn-e-Sina Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
(4 ) Pulmonary Disease Department, Medicine Faculty, Tehran University of Medical Sciences, Tehran , Iran
(5 ) Pathology Department, Medicine Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence

Address: Immunoregulation Research Center, 4th Floor, Shahed University Research Centers Building, No. 1471, Corner of Mehr Alley, North Karegar Street, Enqelab Square, Tehran, Iran
Phone: +98 2166418216
Fax: +98 2166419752
tghazanfari@yahoo.com

Article History

Received:  August  5, 2014
Accepted:  August 25, 2014
ePublished:  February 19, 2015

BRIEF TEXT


… [1-7] Different respiratory diseases such as chronic obstructive pulmonary disease (COPD), respiratory bronchiolitis, obstructive bronchiolitis, emphysema, bronchiectasis, fibrosis, bronchiolitis obliterans, and irritability of the airways, have been shown in the studies about the delayed pulmonary complications due to mustard gas [6, 9-12]. The effective factors on COPD, idiopathic pulmonary fibrosis, and chronic bronchiolitis pathology might play roles in the delayed complications of the lung in the veterans with chemical injuries [9]. … [13] Several complications are due to inflammatory cells in the lung [9, 14]. … [15-21] In the damaged lung tissue in COPD, the lung epithelial cells and alveolar macrophages lead to recruitment of inflammatory cells to the injured site and create an inflammatory focus through secretion of chemokines like CXCL10 [22-24]. In chronic bronchiolitis, alongside the recruitment of the activated T cells, CXCL10, via connecting to CXCR3 on the surface of the epithelial cells of the airways, leads to excessive proliferation of the cells and airways obstruction [24]. CXCL10 plays an important role in fibrosis [25, 26]. … [27-31]

Serum levels of CCL2/MCP1 and macrophages recruitment chemokine in the chemically-injured veterans of Sardasht, Iran, have increased, while CCL5, IL8/CXCL8, and RANTES have decreased [32]. Inflammatory cytokines including IL-1β, IL-1α, IL-1Ra, and TNF, have decreased in the chemically-injured veterans of Sardasht, Iran. In addition, serum levels of soluble P and L selectins of the veterans have decreased, while serum level of soluble E selectin has increased [33, 34].

The aim of this study was to investigate CXCL10 Gene Expression in the lung tissues of chemically-injured veterans.

This is a case-control study.

Lung paraffin blocks of veterans with lung complications exposed to mustard gas, sampled via bronchoscopy method for diagnosis purposes were studied at 2013-14. (The blocks were accessible at the pathology archives of Iran hospitals.)

16 blocks were selected. The samples of non-exposed persons (control group) were taken from archives of the hospitals. 7 paraffin blocks were selected from non-exposed persons, sampled to diagnose lung diseases. Age and sex of the persons were consistent with the exposure group.

Based on the final pathological diagnosis, 3 groups were selected including bronchiolitis obliterans, respiratory bronchiolitis, and antheracosis groups. On the basis, the exposures were divided into 2 groups. 9 samples were included in bronchiolitis obliterans group. 7 samples were included in respiratory bronchiolitis group. On the basis, the non-exposure group was divided into 3 groups including bronchiolitis obliterans (3 samples), respiratory bronchiolitis (1 sample), and antheracosis groups (3 samples). The inclusion criteria were certain exposure to mustard gas (based on the medical records of Martyrs and Veterans Foundation), lung complication (based on the medical records), male, and aged between 30 and 60years. The exclusion criteria were sample loss, insufficient tissues, and cancer cells in the tissue. RNA was extracted from paraffin samples using “RNA Extraction from Paraffin Tissue” kit (Qiagen, Cat: 73504; Germany). At first two 18-micron slices were prepared from the block and then, they were deparaffinized using xylene, at 56°C and for 30min. Absolute alcohol was used to remove xylene. After incubation, one deparaffinized semi-sample with protease K at 45°C was precipitated after passing the RNA column. Finally, the precipitated RNA was dissolved in water free of Rnase/Dnase. The extracted RNA was measured using Nano Drop device (Thermo; USA). To ensure the absence of genomic DNA, some samples were selected randomly and PCR reaction with the extracted RNA product was performed directly and before converting to cDNA with beta-actin primer with the ability to bind to genomic DNA (Table 1). Due to seeing the product band on gel with PCR on the RNA product, treatment was done with DNase I (Fermentas, Cat: EN0521; USA) according to protocol. 1µg RNA product, 2µl MgCl2 with 10Xµl buffer, and 1µl DNase I/RNase-free were added to each reaction and it was reached to 10µl final volume, adding DEPC-treated Water. The samples were incubated for 45min at 37°C and then, 50mmol EDTA was added to hinder Dnase I reaction and it was incubated for 10 more minutes at 56°C. The RNA product, brought at the Dnase I side with the mentioned primer, was converted into PCR for the second time. There was no product due to the PCR and the absence of genomic DNA was confirmed. Then, cDNA was synthesized from the RNA product. The extracted RNA was converted to cDNA, using cDNA Synthesis kit (TAKARA; Japan). To synthesize cDNA, 2µl master mix 2X (TAKARA; Japan) was incubated with 0.5µl oligo primer and 0.5µl random primer with 0.5µl reverse transcriptase enzyme and 500ng of the RNA product in 10µl final volume for 15min and at 37°C (and 5seconds at 85°C to stop the reaction). The primers were designed using NCBI database (Table 1). The favorable conditions for reaction were formed, changing the primer and sample amounts and primer binding temperature. GAPDH gene was considered as reference gene in the analysis of Real-Time PCR results using Livak method (Fig. 1). The functions of the primers were evaluated with positive samples before performing desired stages on Real-Time PCR. The reaction of Real-Time PCR was done using Master Mix containing SYBR Green I (TAKARA, Cat No.: RR820L; Japan) and Real-Time (Applied Biosystem; USA). 20µl reactions were done with 2.5µm cDNA production, 1µl step out primer and 1µl step back primer with 5pmol for CXCL10 and with 10pmol concentration in PCR Real-Time reaction. For GAPDH, 9.6µlit Master Mix and 0.4µlit Rox were done with 1 cycle with 95°C heat for 30seconds, 50 cycles with 95°C heat for 5seconds, and then 50 cycles with 60°C heat for 30seconds and after PCR stages had ended, the melting curve program was performed in the device. Only one pick was observed on the melting curve and the absence of non-specific products was confirmed. Delta CT method was used to investigate relative gene expression. Standard curve was used to compute the efficiency. And 1 to 5 concentrations of control cDNA were used to produce the standard curve. The differences in PCR reaction efficiency of target and standard genes were close to each other [35]. Data was analyzed using SPSS 20 software and Mann-Whitney Test.

At the time of sampling, the mean ages of exposed and non-exposed groups were 41.95±11.13years and 51.02±10.07years, respectively. Delta CT mean values of the veterans and control samples were 7.37±3.58 and 5.81±3.29. There was no significant difference between the groups and between exposed and non-exposed sub-groups. CXCL10 expression patterns in exposure and non-exposed groups with similar pulmonary pathologic disorders were the same (Fig. 1).

Findings by Text: At the time of sampling, the mean ages of exposed and non-exposed groups were 41.95±11.13years and 51.02±10.07years, respectively. Delta CT mean values of the veterans and control samples were 7.37±3.58 and 5.81±3.29. There was no significant difference between the groups and between exposed and non-exposed sub-groups. CXCL10 expression patterns in exposure and non-exposed groups with similar pulmonary pathologic disorders were the same (Fig. 1).

The research ought to be repeated with more samples. CXCL10 in samples such as phlegm and bronchoalveolar lavage, which can show lung tissue situation, ought to be investigated. More studies ought to be done to investigate the correlation between CXCL10 and the severity of the delayed effects. In addition, the level of the chemokine in different injured tissues of the veterans ought to be measured including skin and eyes.

Difficult access to proper samples from archives of the hospitals was one of the limitations for the present study. It was impossible to remove affecting factors, such as consumed medications by the patient, from the study, which might affect the results.

The level and pattern of CXCL10 expression are not different in lung tissues of two exposed and non-exposed groups.

The researcher fells grateful to Immunoregulation Research Center.

Non-declared

All procedures were approved by Ethics Committee of Shahed University.

The study was funded by Immunoregulation Research Center.

TABLES and CHARTS

Show attach file


CITIATION LINKS

[1]Hosseini-khalili A, Haines DD, Modirian E, Soroush M, Khateri S, Joshi R, et al. Mustard gas exposure and carcinogenesis of lung. Mutat Res. 2009;678(1):1-6
[2]Momeni AZ, Enshaeih S, Meghdadi M, Amindjavaheri M. Skin manifestations of mustard gas. A clinical study of 535 patients exposed to mustard gas. Arch Dermatol. 1992;128(6):775-80.
[3]Borak J, Sidell FR. Agents of chemical warfare: Sulfur mustard. Ann Emerg Med. 1992;21(3):303-8.
[4]Rowell M, Kehe K, Balszuweit F, Thiermann H. The chronic effects of sulfur mustard exposure. Toxicology. 2009;263(1):9-11.
[5]Razavi SM, Ghanei M, Salamati P, Safiabadi M. Long-term effects of mustard gas on respiratory system of Iranian veterans after Iraq-Iran war: A review. Chin J Traumatol. 2013;16(3):163-8.
[6]Somani SM, Babu SR. Toxicodynamics of sulfur mustard. Int J Clin Pharmacol Ther Toxicol. 1989;27(9):419-35.
[7]Robert JJ, Warwick GP. Studies of mode of action of alkylation against. VI. The metabolism of BIS-2- chloroethylsulphid (mustard gas) and related compounds. Biochem Pharmacol. 1963;12:1329-34.
[8]Malaviya R, Sunil VR, Cervelli J, Anderson DR, Holmes WW, Conti ML, et al. Inflammatory effects of inhaled sulfur mustard in rat lung. Toxicol Appl Pharmacol. 2010;248(2):89-99.
[9]Ghanei M, Harandi AA. Molecular and cellular mechanism of lung injuries due to exposure to sulfur mustard: A review. Inhal Toxicol. 2011;23(7):363-71.
[10]Emad A, Rezaian GhR. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure analysis of 197 cases. CHEST J. 1997;112(3):734-8.
[11]Myers JL, Colby TV. Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia, and diffuse panbronchiolitis. Clin Chest Med. 1993;14(4):611-22.
[12]Taghaddosinejad F, Fayyaz AF, Behnoush B. Pulmonary complications of mustard gas exposure: a study on cadavers. Acta Med Iran. 2011;49(4):233-6.
[13]Mishra NC, Rir-sima-ah J, Grotendorst GR, Langley RJ, Singh SP, Gundavarapu S, et al. Inhalation of sulfur mustard causes long-term T cell-dependent inflammation: possible role of Th17 cells in chronic lung pathology. Int Immunopharmacol. 2012;13(1):101-8.
[14]Weinberger B, Laskin JD, Sunil VR, Sinko PJ, Heck DE, Laskin DL. Sulfur mustard-induced pulmonary injury: therapeutic approaches to mitigating toxicity. Pulm Pharmacol Ther. 2011;24(1):92-9.
[15]Comerford I, McColl SR. Mini-review series: Focus on chemokines. Immunol Cell Biol. 2011 Feb;89(2):183-4.
[16]Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659-702.
[17]Balestrieri ML, Balestrieri A, Mancini FP, Napoli C. Understanding the immunoangiostatic CXC chemokine network. Cardiovasc Res. 2008;78(2):250-6.
[18]Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, et al. CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68(1):1-8.
[19]Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science. 1999;286(5447):2098-102.
[20]Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest. 2007;117(3):549-56.
[21]Holloway RA, Donnelly LE. Immunopathogenesis of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2013;19(2):95-102.
[22]MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):258-66.
[23]Chen H, Wang D, Wang X. Role of airway epithelium-origin chemokines and their receptors in COPD. J Epithel Biol Pharmacol. 2010;3:26-33.
[24]Jin T, Xu X, Hereld D. Chemotaxis, chemokine receptors and human disease. Cytokine. 2008;44(1):1-8.
[25]Keane MP. The role of chemokines and cytokines in lung fibrosis. Eur Resir Rev. 2008;17(109):151-6.
[26]Dong S, Zhang X, He Y, Xu F, Li D, Xu W, et al. Synergy of IL-27 and TNF-α in regulating CXCL10 expression in lung fibroblasts. Am J Respir Cell Mol Biol. 2013;48(4):518-30.
[27]Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest. 2004;114(2):291-9.
[28]Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med. 2005;171(3):261-8.
[29]Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, Leary CP, et al. Inhibition of pulmonary fibrosis by chemokin IP10/CXCL10. Am J Respir Cell Mol Biol. 2004;31(4):395-404.
[30]Jiang D, Liang J, Guo R, Xie T, Kelly FL, Martinu T, et al. Long-term exposure of chemokine CXCL10 causes bronchiolitis-like inflammation. Am J Respir Cell Mol Biol. 2012;46(5):592-8.
[31]Agostini C, Calabrese F, Poletti V, Marcer G, Facco M, Miorin M, et al. CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis. Respir Res. 2005;22;6:20.
[32]Ghazanfari T, Yaraee R, Kariminia A, Ebtekar M, Faghihzadeh S, Vaez-Mahdavi MR, et al. Alterations in the serum levels of chemokines 20 years after sulfur mustard exposure: Sardasht-Iran Cohort Study. Int Immunopharmacol. 2009;9(13-14):1471-6.
[33]Yaraee R, Ghazanfari T, Ebtekar M, Ardestani SK, Rezaei A, Kariminia A, et al. Alterations in serum levels of inflammatory cytokines (TNF, IL-1alpha, IL-1beta and IL-1Ra) 20 years after sulfur mustard exposure: Sardasht-Iran cohort study. Int Immunopharmacol. 2009;9(13-14):1466-70.
[34]Yaraee R, Ghazanfari T, Faghihzadeh S, Mostafaie A, Soroush MR, Inai K, et al. Alterations in the serum levels of soluble L, P and E-selectin 20 years after sulfur mustard exposure: Sardasht-Iran Cohort Study. Int Immunopharmacol. 2009;9(13-14):1477-81.
[35]Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8.
[36]Ghanei M, Adibi I. Clinical review of mustard lung. Iran J Med Sci. 2007;32(2):58-65.
[37]Lari SM, Attaran D, Towhidi M. COPD Due to Sulfur Mustard (Mustard Lung). In: Ong KCh. Chronic Obstructive Pulmonary Disease - Current Concepts and Practice. Croatia: InTech; 2012. Pp. 231-238.
[38]Attaran D, Lari SM, Khajehdaluee M, Ayatollahi H, Towhidi M, Asnaashari A, et al. Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complication of sulfur mustard poisoning and its correlation with severity of airway diseases. Hum Exp Toxicol. 2009;28(12):739-45.
[39]Attaran D, Lari SM, Towhidi M, Marallu HG, Ayatollahi H, Khajehdaluee M, et al. Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:335-40
[40]Pourfarzam S, Ghazanfari T, Merasizadeh J, Ghanei M, Azimi G, Araghizadeh H, et al. Long-term pulmonary complications in sulfur mustard victims of Sardasht, Iran. Toxin Rev. 2009;28(1):8-13.
[41]Ghanei M, Amiri S, Akbari H, Kosari F, Khalili AR, Alaeddini F, et al. Correlation of sulfur mustard exposure and tobacco use with expression (immunoreactivity) of p53 protein in bronchial epithelium of Iranian "mustard lung" patients. Mil Med. 2007;172(1):70-4.
[42]Medoff BD, Wain JC, Seung E, Jackobek R, Means TK, Ginns LC, et al. CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. J Immunol. 2006;176(11):7087-95.
[43]Beytut E. Anthracosis in the lungs and associated lymph nodes in sheep and its potential role in the occurrence of pneumonia. Small Ruminant Res. 2002;46(1),15-21.
[44]Wang Z, Chen YW, Zhang JN, Hu XF, Peng MJ. Pentoxifylline attenuates cigarette smoke-induced overexpression of CXCR3 and IP-10 in mice. Chin Med J. 2012;125(11):1980-5.
[45]Costa C, Rufino R, Traves SL, Lapa E Silva JR, Barnes PJ, Donnelly LE. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest. 2008;133(1):26-33.
[46]Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(3 Pt 1):822-6.
[47]Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165(10):1404-9.